For many of the world’s most prevalent and life-threatening conditions—ranging from non-alcoholic steatohepatitis (NASH) to acute kidney injury (AKI) and aortic aneurysms—clinical management is currently limited to "watchful waiting," lifestyle changes, or invasive surgery. Despite our deep understanding of their pathology, these diseases exist in a therapeutic vacuum where no FDA-approved pharmacological treatments are available.
A growing body of research is now bridging this gap by moving beyond supportive care toward targeted molecular interventions. By identifying specific metabolic switches, leveraging the gut-organ axis, and repurposing existing drugs, researchers are uncovering the first viable pharmacological pathways to halt or reverse these "untreatable" conditions.
Recalibrating Metabolic Switches
The most common strategy across this research direction is the identification of "master switches" that can be flipped to reset cellular metabolism. In metabolic-associated fatty liver disease (MAFLD) and NASH, the problem is not just the presence of fat, but the failure of the liver to process it.
Yong Zhang and colleagues demonstrated this by using Nootkatone to activate the energy-sensing AMPK pathway while suppressing stress-related MAPK signaling. This dual action effectively "restarts" the liver's energy consumption. Similarly, Yuanyang Zhao showed that the Jiangzhi Capsule works by downregulating SREBP-1c and DGAT-2, the primary machinery responsible for fat synthesis and storage.
This "switch-flipping" approach extends to acute conditions as well. In sepsis-induced kidney damage, Tianyuan Yang found that dexmedetomidine activates the α2-AR/AMPK/mTOR pathway to restart autophagy—the cell's internal recycling system—which prevents the lethal inflammatory surge of the NLRP3 inflammasome.
The Gut-Organ Axis as a Drug Factory
A second major frontier involves treating systemic diseases by modulating the gut microbiome. Rather than targeting the liver or pancreas directly, researchers are using the gut as a "bioreactor" to produce therapeutic metabolites.
Wenchao Wei identified a specific gut-liver axis pathway where dietary inulin promotes the growth of Parabacteroides distasonis. This bacterium produces pentadecanoic acid, which repairs the gut barrier and suppresses liver inflammation. This shift toward "metabolic engineering" via the microbiome is also seen in acute pancreatitis, where L Wang discovered that deoxycholic acid (a bile acid) activates the PPAR signaling pathway to mitigate pancreatic damage.
Molecular Quality Control and Repurposing
When a disease lacks a dedicated drug, researchers often look for "quality control" mechanisms that already exist in the body but have failed. Lang Jiang identified LAPTM5 as a protein that acts as a cellular trash-collector, sending harmful signaling proteins to the lysosome for degradation. Enhancing this natural "waste management" system provides a blueprint for treating NASH without introducing entirely foreign chemical pathways.
This logic extends to drug repurposing, where medications approved for other conditions are tested against these therapeutic gaps:
- Cancer Drugs: Zhuomiao Lin found that the leukemia drug Ponatinib restores liver autophagy by activating the master regulator TFEB.
- Diabetes Drugs: Xueyan Lv highlighted the potential of SGLT-2 inhibitors to reduce liver fat and inflammation.
- Hypertension Drugs: Yu Wu provided evidence that ACE inhibitors and ARBs offer secondary hepatoprotective benefits for patients with steatotic liver disease.
From Supportive Care to Precision Intervention
The unifying goal of these diverse studies—whether using selenium nanoparticles for the pancreas or cockroach extracts for the liver—is to move away from treating symptoms and toward addressing the underlying biological drivers.
As Zhicheng Wang argues in the context of aortic valve disease, we must stop viewing these conditions as passive "wear-and-tear" and start treating them as active, immune-mediated processes. By identifying causal drivers like FGF23 or mechanical triggers like podosome formation, the field is finally moving toward a future where "watchful waiting" is replaced by active pharmacological rescue.